Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19772489 | 0.89 | MEN1 (0.36) | TSHRTP53TDP1 | |
| SCHEMBL25463304 | 0.89 | TSHR (0.39) | TSHRTP53TDP1PPARDNPSR1 | |
| SCHEMBL4757795 | 0.85 | TSHR (0.43) | TSHRTP53TDP1PPARDNPSR1 | |
| SCHEMBL3146731 | 0.79 | TSHR (0.48) | TSHRTP53TDP1PPARDNPSR1 | |
| SCHEMBL9614639 | 0.79 | TSHR (0.48) | TSHRTP53TDP1PPARDNPSR1 | |
| SCHEMBL10426582 | 0.79 | TSHR (0.48) | TSHRTP53TDP1PPARD | |
| SCHEMBL4434268 | 0.79 | TSHR (0.48) | TSHRTP53TDP1PPARD | |
| SCHEMBL18087213 | 0.78 | TSHR (0.42) | TSHRTP53TDP1PPARDNPSR1 | |
| SCHEMBL10128271 | 0.77 | TSHR (0.46) | TSHRTP53TDP1PPARD | |
| SCHEMBL3502263 | 0.76 | TSHR (0.40) | TSHRTP53TDP1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1032 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036711-A | Pyricularia sulfone Synthesis method of intermediate | 山东潍坊润丰化工股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-114085234-B | Process for preparing 1, 3-benzodioxole heterocyclic compounds | 联合疗法公司 | 2024-12-17 | — | — | CN | claimed |
| EP-3390407-B1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | UNION THERAPEUTICS AS (DK) | 2023-10-11 | — | — | EP | claimed |
| US-11760701-B2 | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YROK (US) | 2023-09-19 | — | — | US | claimed |
| US-20230073362-A1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | UNION therapeutics A/S (DK) | 2023-03-09 | — | — | US | claimed |
| US-11370799-B2 | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | UNION therapeutics A/S (DK) | 2022-06-28 | — | — | US | claimed |
| US-20220162227-A1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | UNION therapeutics A/S (DK) | 2022-05-26 | — | — | US | claimed |
| US-20200262842-A1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | UNION therapeutics A/S (DK) | 2020-08-20 | — | — | US | claimed |
| US-12637435-B2 | Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof | FUJIFILM CORPORATION (JP) | 2026-05-26 | — | — | US | disclosed |
| CN-122074043-A | Combination therapy with KRAS modulators | 光达治疗公司 | 2026-05-22 | — | — | CN | disclosed |
| WO-2026107227-A1 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-12630514-B2 | Process and intermediates for the preparation of pyroxasulfone | ADAMA AGAN LTD. (IL) | 2026-05-19 | — | — | US | disclosed |
| US-5538978-A | NUCLEOSIDE PHOSPHORYLASE INHIBITORS AS IMMUNOSUPPRESSANTS, ANTILYMPHOMA, ANTILEUKEMIA, VIRICIDES AND ANTIPROTOZOA AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-23 | — | — | US | disclosed |
| US-5527803-A | IMMUNOSUPPRESSANTS, PHOSPHORYLASE INHIBITORS | MERRELL PHARMACEUTICALS INC. (US) | 1996-06-18 | — | — | US | disclosed |
| US-5494912-A | 9-purinyl phosphonic acid derivitives for treating gout | MERRELL PHARMACEUTICALS INC. (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0465297-B1 | 9-Purinyl phosphonic acid derivatives | MERRELL DOW PHARMA (US) | 1996-01-31 | — | — | EP | disclosed |
| EP-0531597-A1 | Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0465297-A1 | 9-Purinyl phosphonic acid derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262842-A1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | PDE4B, PDE4A, PDE4C | TSHR 3441/4885TP53 4715/4885TDP1 203/4885 |
| US-20230073362-A1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | PDE4B, PDE4A, PDE3B | TSHR 3679/4885TP53 4701/4885TDP1 183/4885 |
| US-12630514-B2 | Process and intermediates for the preparation of pyroxasulfone | MRPS23, CYP2E1, CYP2S1 | TSHR 1582/4885TP53 2598/4885TDP1 2101/4885 |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNND1, CTNNA1 | TSHR 4681/4885TP53 61/4885TDP1 861/4885 |
| US-12637435-B2 | Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof | CBR1, DHODH, CBR3 | TSHR 2492/4885TP53 686/4885TDP1 2604/4885 |
| US-11760701-B2 | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same | AFF2, AFF4, AFF1 | TSHR 2337/4885TP53 1099/4885TDP1 2207/4885 |
| US-20220162227-A1 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | PDE4B, PDE4A, PDE4C | TSHR 3696/4885TP53 4732/4885TDP1 185/4885 |
| US-11370799-B2 | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | PDE4B, PDE4A, PDE4C | TSHR 3441/4885TP53 4715/4885TDP1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.